KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies

Survival of patients with metastatic CRC (mCRC) has improved steadily over the past several decades, due largely to the development of new combinations of standard chemotherapy, as well as to the introduction of new targeted therapies. Among the available targeted therapies are two monoclonal antibo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Soulières, D., Greer, W., Magliocco, Anthony M., Huntsman, D., Young, S., Tsao, M.-S., Kamel-Reid, S.
Format: Artigo
Idioma:Inglês
Publicat: Multimed Inc. 2010
Matèries:
Medical Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2901795/
https://ncbi.nlm.nih.gov/pubmed/20680106
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars